BAMI试验:急性心肌梗死冠脉内输注骨髓单核细胞对全因死亡率的影响
BAMI原为开放标签多中心III期试验,旨在评估ST段抬高型心肌梗死PCI后LVEF≤45%患者冠脉内输注BM-MNC能否降低全因死亡时间。因入组意外偏低,试验降级为观察性研究,共375例(治疗组185例、对照组190例)。2年全因死亡率两组分别为3.26%与3.82%,心衰住院率治疗组2.7%、对照组8.1%,不良事件无差异,但低入组与低事件率使组间比较无法得出确定性结论。
要点
- BAMI是迄今最大规模的自体细胞治疗AMI试验,但入组与事件率意外偏低,无法进行有意义的组间比较。
- 2年全因死亡率BM-MNC组3.26%、对照组3.82%,心衰住院率分别为2.7%和8.1%。
- 两组不良事件与严重不良事件无差异,但研究降级为观察性研究,不能据此得出疗效结论。
核心结论
- BAMI是急性心肌梗死自体细胞治疗领域最大规模的试验,但入组和事件率意外偏低,无法对观察结果做有意义的组间比较和解读。
研究设计与样本
- 原设计为开放标签、多中心III期试验,旨在证明ST段抬高型心肌梗死直接PCI后LVEF≤45%患者冠脉内输注BM-MNC缩短全因死亡时间的安全性和有效性。
- 因入组意外偏低,试验不再符合假设检验试验条件,转为观察性研究,统计分析无法得出确定性结论。
- 共入组375例:治疗组185例在PPCI后2-8天接受冠脉内BM-MNC输注,对照组190例接受最佳药物治疗。
主要发现
- 2年全因死亡率:BM-MNC组3.26%(6例死亡,95%CI 1.48-7.12%),对照组3.82%(7例死亡,95%CI 1.84-7.84%)。
- 2年随访期间因心力衰竭住院:BM-MNC组5例(2.7%,95%CI 1.0-5.9%),对照组15例(8.1%,95%CI 4.7-12.5%)。
- 两组不良事件及严重不良事件无差异;对照组无卒中住院患者,BM-MNC组有4例(2.2%)因卒中住院。
临床怎么用
- 目前证据不支持将冠脉内BM-MNC输注作为ST段抬高型心肌梗死PCI后的常规治疗。
- 解读该试验结果时需注意其因入组不足已降级为观察性研究,不能据此推断疗效。
局限性
- 入组人数意外偏低,试验降级为观察性研究,无法进行有意义的组间比较。
- 事件率意外偏低,统计分析无法得出确定性结论。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Bone marrow-derived mononuclear cell (BM-MNC) therapy may improve myocardial recovery in patients following acute myocardial infarction (AMI), though existing trial results are inconsistent. METHODS AND RESULTS: Originally an open-label, multicentre Phase III trial, BAMI was designed to demonstrate the safety and efficacy of intracoronary infusion of BM-MNCs in reducing the time to all-cause mortality in patients with reduced left ventricular ejection fraction (LVEF, ≤45%) after primary angioplasty (PPCI) for ST-elevation AMI. Unexpectedly low recruitment means the trial no longer qualifies as a hypothesis-testing trial, but is instead an observational study with no definitive conclusions possible from statistical analysis. In total, 375 patients were recruited: 185 patients were randomized to the treatment arm (intracoronary infusion of BM-MNCs 2-8 days after PPCI) and 190 patients to the control arm (optimal medical therapy). All-cause mortality at 2 years was 3.26% [6 deaths; 95% confidence interval (CI): 1.48-7.12%] in the BM-MNC group and 3.82% (7 deaths; 95% CI: 1.84-7.84%) in the control group. Five patients (2.7%, 95% CI: 1.0-5.9%) in the BM-MNC group and 15 patients (8.1%, CI : 4.7-12.5%) in the control group were hospitalized for heart failure during 2 years of follow-up. Neither adverse events nor serious adverse events differed between the two groups. There were no patients hospitalized for stroke in the control group and 4 (2.2%) patients hospitalized for stroke in the BM-MNC group. CONCLUSIONS: Although BAMI is the largest trial of autologous cell-based therapy in the treatment of AMI, unexpectedly low recruitment and event rates preclude any meaningful group comparisons and interpretation of the observed results.
引用
- Mathur A, Fernández-Avilés F, Bartunek J, et al. The effect of intracoronary infusion of bone marrow-derived mononuclear cells on all-cause mortality in acute myocardial infarction: the BAMI trial. Eur Heart J. 2020. PMID: 32860406. doi:10.1093/eurheartj/ehaa651
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。